Sanofi successfully prices EUR 1.5 billion of bond issue
March 24 2020 - 5:00PM
Sanofi successfully prices EUR 1.5 billion of bond issue
Sanofi successfully prices EUR 1.5 billion of bond
issue
Paris, France – March 24, 2020
- Sanofi (EURONEXT: SAN and NASDAQ: SNY) announces that it has
successfully priced its offering of EUR 1.5 billion of notes (the
“Notes”) across 2 tranches:
- €750 million fixed rate notes, due April 2025, bearing interest
at an annual rate of 1.000 %
- €750 million fixed rate notes, due April 2030, bearing interest
at an annual rate of 1.500%.
The Notes are being issued off the company's
Euro Medium Term Note Programme.
The transaction enables the company to lower its
average cost of debt and extend the average maturity of its
debt.
Sanofi intends to use the net proceeds of the
offering for general corporate purposes.
BofA Securities, Crédit Agricole CIB, HSBC and
Société Générale acted as Global Coordinators and Bookrunners for
the offering.
DISCLAIMER
This communication shall not constitute an offer
to sell or the solicitation of an offer to buy nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
The Notes have not been and will not be
registered under the Securities Act and may not be offered or sold
within the United States or to, or for the account or benefit of,
U.S. persons except in certain transactions exempt from the
registration requirements of the Securities Act.
PROHIBITION OF SALES TO EUROPEAN
ECONOMIC AREA ("EEA") AND UNITED KINGDOM ("UK") RETAIL INVESTORS
– The Notes are not intended to be offered, sold or
otherwise made available to and should not be offered, sold or
otherwise made available to any retail investor in the EEA and in
the UK. For these purposes, a retail investor means a person who is
one (or more) of: (i) a retail client as defined in point (11) of
Article 4(1) of Directive 2014/65/EU ("MiFID II");
or (ii) a customer within the meaning of Directive (EU) 2016/97 (as
amended or superseded the "Insurance Mediation
Directive"), where that customer would not qualify as a
professional client as defined in point (10) of Article 4(1) of
MiFID II. Consequently no key information document required by
Regulation (EU) No 1286/2014 (as amended, the "PRIIPs
Regulation") for offering or selling the Notes or
otherwise making them available to retail investors (as defined
above) in the EEA or in the UK has been or will be prepared and
therefore offering or selling the Notes or otherwise making them
available to any such retail investor in the EEA or in the UK may
be unlawful under the PRIIPS Regulation.
This communication is only being distributed to
and is only directed at (i) persons who are outside the United
Kingdom or (ii) investment professionals falling within Article
19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005 (the "Order") or (iii) high
net worth companies, and other persons to whom it may lawfully be
communicated, falling within Article 49(2)(a) to (d) of the Order
or (iv) persons to whom an invitation or inducement to engage in
investment activity (within the meaning of section 21 of the
Financial Services and Markets Act 2000) may otherwise lawfully be
communicated or cause to be communicated (all such persons together
being referred to as “relevant persons”). The Notes are only
available to, and any invitation, offer or agreement to subscribe,
purchase or otherwise acquire such Notes will be engaged in only
with, relevant persons. Any person who is not a relevant person
should not act or rely on this document or any of its contents.
Notes have only been offered or sold and will
only be offered or sold, directly or indirectly, in France to
qualified investors (investisseurs qualifiés) as defined in Article
L.411-2 1° of the French Code monétaire et financier, and the Base
Prospectus, any Final Terms or any other offering material relating
to the Notes have only been distributed or caused to be distributed
and will only be distributed or caused to be distributed in France
to such qualified investors.
About Sanofi Sanofi is dedicated to
supporting people through their health challenges. We are a global
biopharmaceutical company focused on human health. We prevent
illness with vaccines, provide innovative treatments to fight pain
and ease suffering. We stand by the few who suffer from rare
diseases and the millions with long-term chronic
conditions. With more than 100,000 people in 100 countries,
Sanofi is transforming scientific innovation into healthcare
solutions around the globe. Sanofi, Empowering Life |
Media Relations Contact Quentin Vivant Tel.: +33
(0)1 53 77 46 46 mr@sanofi.com |
Investor
Relations Contact Félix Lauscher Tel.: +33 (0)1 53 77 45
45 ir@sanofi.com |
Sanofi Forward-Looking
StatementsAny statements made in this communication that
are not statements of historical fact, including statements about
Sanofi’s beliefs and expectations are forward-looking statements
and should be evaluated as such. Forward-looking statements include
statements that may relate to Sanofi‘s plans, objectives,
strategies, goals, future events, future revenues or performance,
and other information that is not historical information. Sanofi
does not undertake, and specifically disclaims, any obligation or
responsibility to update or amend any of the information above
except as otherwise required by law.Additional
InformationThis communication is neither an offer to
purchase nor a solicitation of any offer to sell any securities,
nor shall there be any sale of securities in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
jurisdiction. |
Sanofi (EU:SAN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sanofi (EU:SAN)
Historical Stock Chart
From Apr 2023 to Apr 2024